Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cabozantinib With or Without Atezolizumab in Advanced Papillary Renal Cell Carcinoma (PAPMET2)
NCT05411081Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Mar 2023
- Primary completion
- Jul 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in papillary renal cell carcinoma (PRCC), sponsored by National Cancer Institute. Started Mar 2023; status: active, not recruiting.
02
Drugs
atezolizumab
03
Conditions
papillary renal cell carcinoma (PRCC)
Beyond the preview
Go deeper on NCT05411081.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05411081.